10x Genomics reports strong Atera demand in Q2 earnings

10x Genomics announced its second‑quarter 2026 results, reporting revenue of $151 million, a 3 % year‑over‑year increase after excluding $1.6 million of settlement‑related income. The company posted a net loss of $17.9 million, compared with a net profit a year earlier, and raised its full‑year revenue outlook to $610‑$630 million.

Management highlighted an "extraordinary" customer response to the Atera spatial‑biology platform, with early order flow exceeding expectations and driving strong engagement across universities, medical centers and biopharma partners. The quarter also saw the acquisition of Proteintech Genomics to add protein‑detection capabilities, and the launch of multi‑year research collaborations with the Cleveland Clinic and Lausanne University Hospital to advance cancer diagnostics using single‑cell and spatial technologies.